A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral-Quantitative Computed Tomography (p-QCT). - STRATEC

• Conditions: Post-menopausal osteoporosis; MedDRA version: 9.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausal

• Registration Number: EUCTR2007-001509-11-GR
• Lead Sponsor: Institut de Recherches Internationales Servier

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10-29
• Last Update Posted: 17 July 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Female
• Target Recruitment: 80

Inclusion Criteria

- Women of at least 50 years
- Postmenopausal for at least 5 years
- Osteoporosis
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Evolutive cancers during the past 5 years with a risk of bone metastases
- BMI less than 18 or higher than 30 kg/m²
- Severe malabsorption

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified